Skip to main content
Erschienen in: Familial Cancer 1/2007

01.03.2007 | Original Paper

Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies

verfasst von: R. C. Green, J. S. Green, S. K. Buehler, J. D. Robb, D. Daftary, S. Gallinger, J. R. McLaughlin, P. S. Parfrey, H. B. Younghusband

Erschienen in: Familial Cancer | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Newfoundland has the highest rate of colorectal cancer (CRC) of any Canadian province. In order to investigate the factors, especially genetic components, responsible for CRC we established the Newfoundland Colorectal Cancer Registry. In a 5-year period we examined every case of CRC diagnosed under the age of 75 years and obtained consent from 730 cases. Careful analysis of family history was used to assign a familial cancer risk, based on established criteria. We observed that 3.7% of CRC cases came from families meeting the Amsterdam II criteria and a further 0.9% of cases involved familial adenomatous polyposis (FAP). An additional 43% of cases met one or more of the revised Bethesda criteria and 31% of all cases had a first-degree relative affected with CRC. We compared the Newfoundland data with data from the province of Ontario, where the same recruitment and risk-assessment criteria were used. In all categories, the indicators of familial risk were significantly higher in Newfoundland. These data were also compared to results published from 13 other population-based studies worldwide. In every category the proportion of Newfoundland cases meeting the criteria was higher than in any other population. The mean differences were: 3.5-fold greater for FAP, 2.8-fold higher for Amsterdam criteria, 2.0-fold higher for Bethesda criteria and 1.9-fold higher for the number of affected first-degree relatives. We conclude that the high incidence of CRC in Newfoundland may be attributable to genetic, or at least familial, factors. In the high-risk families we provide evidence for the involvement of founder mutations in the APC and MSH2 genes.
Literatur
1.
Zurück zum Zitat National Cancer Institute of Canada (2003) Canadian cancer statistics 2003. Toronto, Canada National Cancer Institute of Canada (2003) Canadian cancer statistics 2003. Toronto, Canada
3.
Zurück zum Zitat Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G et al (1993) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75:951–957PubMedCrossRef Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G et al (1993) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75:951–957PubMedCrossRef
4.
Zurück zum Zitat Lamlum H, Al Tassan N, Jaeger E, Frayling I, Sieber O, Reza FB et al (2000) Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet 9:2215–2221PubMed Lamlum H, Al Tassan N, Jaeger E, Frayling I, Sieber O, Reza FB et al (2000) Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet 9:2215–2221PubMed
5.
Zurück zum Zitat Peltomaki P (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21:1174–1179PubMedCrossRef Peltomaki P (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21:1174–1179PubMedCrossRef
6.
Zurück zum Zitat Narayan S, Roy D (2003) Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2:41–55PubMedCrossRef Narayan S, Roy D (2003) Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2:41–55PubMedCrossRef
7.
Zurück zum Zitat Aaltonen LA, Peltomäki P, Mecklin J-P, Järvinen H, Jass JR, Green JS et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed Aaltonen LA, Peltomäki P, Mecklin J-P, Järvinen H, Jass JR, Green JS et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed
8.
Zurück zum Zitat Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425PubMedCrossRef Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425PubMedCrossRef
9.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
10.
Zurück zum Zitat Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRef Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRef
11.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP, Syngal S, De La CA, Ruschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef Umar A, Boland CR, Terdiman JP, Syngal S, De La CA, Ruschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef
12.
Zurück zum Zitat Slattery ML, Levin TR, Ma K, Goldgar D, Holubkov R, Edwards S (2003) Family history and colorectal cancer: predictors of risk. Cancer Causes Control 14:879–887PubMedCrossRef Slattery ML, Levin TR, Ma K, Goldgar D, Holubkov R, Edwards S (2003) Family history and colorectal cancer: predictors of risk. Cancer Causes Control 14:879–887PubMedCrossRef
13.
Zurück zum Zitat Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef
14.
Zurück zum Zitat Ainsworth PJ, Koscinski D, Fraser BP, Stuart JA (2004) Family cancer histories predictive of a high risk of hereditary non-polyposis colorectal cancer associate significantly with a genomic rearrangement in hMSH2 or hMLH1. Clin Genet 66:183–188PubMedCrossRef Ainsworth PJ, Koscinski D, Fraser BP, Stuart JA (2004) Family cancer histories predictive of a high risk of hereditary non-polyposis colorectal cancer associate significantly with a genomic rearrangement in hMSH2 or hMLH1. Clin Genet 66:183–188PubMedCrossRef
15.
Zurück zum Zitat Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474–480PubMedCrossRef Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474–480PubMedCrossRef
16.
Zurück zum Zitat Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–1985PubMedCrossRef Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–1985PubMedCrossRef
17.
Zurück zum Zitat Boland CR (2005) Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4:211–218PubMedCrossRef Boland CR (2005) Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4:211–218PubMedCrossRef
18.
Zurück zum Zitat Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S et al (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95:8698–8702PubMedCrossRef Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S et al (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95:8698–8702PubMedCrossRef
19.
Zurück zum Zitat Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875PubMedCrossRef Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875PubMedCrossRef
20.
Zurück zum Zitat Cotterchio M, Keown-Eyssen G, Sutherland H, Buchan G, Aronson M, Easson AM et al (2000) Ontario familial colon cancer registry: methods and first-year response rates. Chronic Dis Can 21:81–86PubMed Cotterchio M, Keown-Eyssen G, Sutherland H, Buchan G, Aronson M, Easson AM et al (2000) Ontario familial colon cancer registry: methods and first-year response rates. Chronic Dis Can 21:81–86PubMed
21.
Zurück zum Zitat Cotterchio M, Manno M, Klar N, McLaughlin J, Gallinger S (2005) Colorectal screening is associated with reduced colorectal cancer risk: a case–control study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control 16:865–875PubMedCrossRef Cotterchio M, Manno M, Klar N, McLaughlin J, Gallinger S (2005) Colorectal screening is associated with reduced colorectal cancer risk: a case–control study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control 16:865–875PubMedCrossRef
22.
Zurück zum Zitat Green RC, McLaughlin JR, Younghusband HB (2005) SISE matters: the Sum of Information on Seventy-yr-old Equivalents measures pedigree information content when assessing the risk of HNPCC in a family. Fam Cancer 4:169–175PubMedCrossRef Green RC, McLaughlin JR, Younghusband HB (2005) SISE matters: the Sum of Information on Seventy-yr-old Equivalents measures pedigree information content when assessing the risk of HNPCC in a family. Fam Cancer 4:169–175PubMedCrossRef
23.
Zurück zum Zitat St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES (1993) Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 118:785–790PubMed St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES (1993) Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 118:785–790PubMed
24.
Zurück zum Zitat Mecklin JP, Jarvinen HJ, Hakkiluoto A, Hallikas H, Hiltunen KM, Harkonen N et al (1995) Frequency of hereditary nonpolyposis colorectal cancer. A prospective multicenter study in Finland. Dis Colon Rectum 38:588–593PubMedCrossRef Mecklin JP, Jarvinen HJ, Hakkiluoto A, Hallikas H, Hiltunen KM, Harkonen N et al (1995) Frequency of hereditary nonpolyposis colorectal cancer. A prospective multicenter study in Finland. Dis Colon Rectum 38:588–593PubMedCrossRef
25.
Zurück zum Zitat Olsson L, Lindblom A (2003) Family history of colorectal cancer in a Sweden county. Fam Cancer 2:87–93PubMedCrossRef Olsson L, Lindblom A (2003) Family history of colorectal cancer in a Sweden county. Fam Cancer 2:87–93PubMedCrossRef
26.
Zurück zum Zitat Evans DG, Walsh S, Jeacock J, Robinson C, Hadfield L, Davies DR et al (1997) Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg 84:1281–1285PubMedCrossRef Evans DG, Walsh S, Jeacock J, Robinson C, Hadfield L, Davies DR et al (1997) Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg 84:1281–1285PubMedCrossRef
27.
Zurück zum Zitat Cravo ML, Fidalgo PO, Lage PA, Albuquerque CM, Chaves PP, Claro I et al (1999) Validation and simplification of Bethesda guidelines for identifying apparently sporadic forms of colorectal carcinoma with microsatellite instability. Cancer 85:779–785PubMedCrossRef Cravo ML, Fidalgo PO, Lage PA, Albuquerque CM, Chaves PP, Claro I et al (1999) Validation and simplification of Bethesda guidelines for identifying apparently sporadic forms of colorectal carcinoma with microsatellite instability. Cancer 85:779–785PubMedCrossRef
28.
Zurück zum Zitat De Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M et al (1999) Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut 45:32–38PubMedCrossRef De Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M et al (1999) Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut 45:32–38PubMedCrossRef
29.
Zurück zum Zitat Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780–790PubMedCrossRef Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780–790PubMedCrossRef
30.
Zurück zum Zitat Katballe N, Christensen M, Wikman FP, Orntoft TF, Laurberg S (2002) Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 50:43–51PubMedCrossRef Katballe N, Christensen M, Wikman FP, Orntoft TF, Laurberg S (2002) Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 50:43–51PubMedCrossRef
31.
Zurück zum Zitat Furukawa T, Konishi F, Shitoh K, Kojima M, Nagai H, Tsukamoto T (2002) Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 94:911–920PubMedCrossRef Furukawa T, Konishi F, Shitoh K, Kojima M, Nagai H, Tsukamoto T (2002) Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 94:911–920PubMedCrossRef
32.
Zurück zum Zitat Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S (2004) Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2:813–819PubMedCrossRef Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S (2004) Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2:813–819PubMedCrossRef
33.
Zurück zum Zitat Pinol V, Andreu M, Castells A, Paya A, Bessa X, Rodrigo J (2004) Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol 16:39–45PubMedCrossRef Pinol V, Andreu M, Castells A, Paya A, Bessa X, Rodrigo J (2004) Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol 16:39–45PubMedCrossRef
34.
Zurück zum Zitat Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer1. JAMA 293:1986–1994PubMedCrossRef Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer1. JAMA 293:1986–1994PubMedCrossRef
35.
Zurück zum Zitat Kerber RA, Neklason DW, Samowitz WS, Burt RW (2005) Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Fam Cancer 4:239–244PubMedCrossRef Kerber RA, Neklason DW, Samowitz WS, Burt RW (2005) Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Fam Cancer 4:239–244PubMedCrossRef
36.
Zurück zum Zitat Sarroca C, Valle AD, Fresco R, Renkonen E, Peltomaki P, Lynch H (2005) Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clin Genet 68:80–87PubMedCrossRef Sarroca C, Valle AD, Fresco R, Renkonen E, Peltomaki P, Lynch H (2005) Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clin Genet 68:80–87PubMedCrossRef
37.
Zurück zum Zitat Spirio L, Green J, Robertson J, Robertson M, Otterud B, Sheldon J et al (1999) The identical 5′ splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. Hum Genet 105:388–398PubMedCrossRef Spirio L, Green J, Robertson J, Robertson M, Otterud B, Sheldon J et al (1999) The identical 5′ splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. Hum Genet 105:388–398PubMedCrossRef
38.
Zurück zum Zitat Froggatt NJ, Green J, Brassett C, Evans DG, Bishop DT, Kolodner R et al (1999) A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer [In Process Citation]. J Med Genet 36:97–102PubMed Froggatt NJ, Green J, Brassett C, Evans DG, Bishop DT, Kolodner R et al (1999) A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer [In Process Citation]. J Med Genet 36:97–102PubMed
39.
Zurück zum Zitat Woods MO, Hyde AJ, Curtis FK, Stuckless S, Green JS, Pollett AF et al (2005) High frequency of hereditary colorectal cancer in Newfoundland likely involves Novel Susceptibility Genes. Clin Cancer Res 11:6853–6861PubMedCrossRef Woods MO, Hyde AJ, Curtis FK, Stuckless S, Green JS, Pollett AF et al (2005) High frequency of hereditary colorectal cancer in Newfoundland likely involves Novel Susceptibility Genes. Clin Cancer Res 11:6853–6861PubMedCrossRef
40.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer). N Engl J Med 352:1851–1860PubMedCrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer). N Engl J Med 352:1851–1860PubMedCrossRef
41.
Zurück zum Zitat Percesepe A, Anti M, Roncucci L, Armelao F, Marra G, Pahor M et al (1995) The effect of family size on estimates of the frequency of hereditary non-polyposis colorectal cancer. Br J Cancer 72:1320–1323PubMed Percesepe A, Anti M, Roncucci L, Armelao F, Marra G, Pahor M et al (1995) The effect of family size on estimates of the frequency of hereditary non-polyposis colorectal cancer. Br J Cancer 72:1320–1323PubMed
42.
Zurück zum Zitat Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMedCrossRef Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMedCrossRef
43.
Zurück zum Zitat Grewal KK, Stefanelli MG, Meijer IA, Hand CK, Rouleau GA, Ives EJ (2004) A founder effect in three large Newfoundland families with a novel clinically variable spastic ataxia and supranuclear gaze palsy. Am J Med Genet A 131:249–254PubMedCrossRef Grewal KK, Stefanelli MG, Meijer IA, Hand CK, Rouleau GA, Ives EJ (2004) A founder effect in three large Newfoundland families with a novel clinically variable spastic ataxia and supranuclear gaze palsy. Am J Med Genet A 131:249–254PubMedCrossRef
44.
Zurück zum Zitat Young TL, Woods MO, Parfrey PS, Green JS, Hefferton D, Davidson WS (1999) A founder effect in the Newfoundland population reduces the Bardet–Biedl syndrome I (BBS1) interval to 1 cM. Am J Hum Genet 65:1680–1687PubMedCrossRef Young TL, Woods MO, Parfrey PS, Green JS, Hefferton D, Davidson WS (1999) A founder effect in the Newfoundland population reduces the Bardet–Biedl syndrome I (BBS1) interval to 1 cM. Am J Hum Genet 65:1680–1687PubMedCrossRef
45.
Zurück zum Zitat Parfrey PS, Davidson WS, Green JS (2002) Clinical and genetic epidemiology of inherited renal disease in Newfoundland. Kidney Int 61:1925–1934PubMedCrossRef Parfrey PS, Davidson WS, Green JS (2002) Clinical and genetic epidemiology of inherited renal disease in Newfoundland. Kidney Int 61:1925–1934PubMedCrossRef
46.
Zurück zum Zitat Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB et al (1998) Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat 11:264–269PubMedCrossRef Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB et al (1998) Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat 11:264–269PubMedCrossRef
47.
Zurück zum Zitat Croitoru ME, Cleary SP, Di NN, Manno M, Selander T, Aronson M et al (2004) Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96:1631–1634PubMedCrossRef Croitoru ME, Cleary SP, Di NN, Manno M, Selander T, Aronson M et al (2004) Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96:1631–1634PubMedCrossRef
Metadaten
Titel
Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies
verfasst von
R. C. Green
J. S. Green
S. K. Buehler
J. D. Robb
D. Daftary
S. Gallinger
J. R. McLaughlin
P. S. Parfrey
H. B. Younghusband
Publikationsdatum
01.03.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Familial Cancer / Ausgabe 1/2007
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-006-9104-x

Weitere Artikel der Ausgabe 1/2007

Familial Cancer 1/2007 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.